TITLE

A Randomized Controlled Trial of Folate Supplementation When Treating Malaria in Pregnancy with Sulfadoxine-Pyrimethamine

AUTHOR(S)
Ouma, Peter; Parise, Monica E.; Hamel, Mary J.; Ter Kuile, Feiko O.; Otieno, Kephas; Ayisi, John G.; Kager, Piet A.; Steketee, Richard W.; Slutsker, Laurence; Van Eijk, Anna M.
PUB. DATE
October 2006
SOURCE
PLoS Clinical Trials;Oct2006, Vol. 3 Issue 10, p0001
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives: Sulfadoxine-pyrimethamine (SP) is an antimalarial drug that acts on the folate metabolism of the malaria parasite. We investigated whether folate (FA) supplementation in a high or a low dose affects the efficacy of SP for the treatment of uncomplicated malaria in pregnant women. Design: This was a randomized, placebo-controlled, double-blind trial. Setting: The trial was carried out at three hospitals in western Kenya. Participants: The participants were 488 pregnant women presenting at their first antenatal visit with uncomplicated malaria parasitaemia (density of ≥ 500 parasites/µl), a haemoglobin level higher than 7 g/dl, a gestational age between 17 and 34 weeks, and no history of antimalarial or FA use, or sulfa allergy. A total of 415 women completed the study. Interventions: All participants received SP and iron supplementation. They were randomized to the following arms: FA 5 mg, FA 0.4 mg, or FA placebo. After 14 days, all participants continued with FA 5 mg daily as per national guidelines. Participants were followed at days 2, 3, 7, 14, 21, and 28 or until treatment failure. Outcome Measures: The outcomes were SP failure rate and change in haemoglobin at day 14. Results: The proportion of treatment failure at day 14 was 13.9% (19/137) in the placebo group, 14.5% (20/138) in the FA 0.4 mg arm (adjusted hazard ratio [AHR], 1.07; 98.7% confidence interval [CI], 0.48 to 2.37; p=0.8), and 27.1% (38/140) in the FA 5 mg arm (AHR, 2.19; 98.7% CI, 1.09 to 4.40; p = 0.005). The haemoglobin levels at day 14 were not different relative to placebo (mean difference for FA 5 mg, 0.17 g/dl; 98.7% CI, -0.19 to 0.52; and for FA 0.4 mg, 0.14 g/dl; 98.7% CI, -0.21 to 0.49). Conclusions: Concomitant use of 5 mg FA supplementation compromises the efficacy of SP for the treatment of uncomplicated malaria in pregnant women. Countries that use SP for treatment or prevention of malaria in pregnancy need to evaluate their antenatal policy on timing or dose of FA supplementation.
ACCESSION #
24839178

 

Related Articles

  • Assessment of Markers of Antimalarial Drug Resistance in Plasmodium falciparum Isolates from Pregnant Women in Lagos, Nigeria. Agomo, Chimere Obiora; Oyibo, Wellington Aghoghovwia; Sutherland, Colin; Hallet, Rachael; Oguike, Mary // PLoS ONE;1/25/2016, Vol. 11 Issue 1, p1 

    Background: The use of antimalarial drugs for prevention and treatment is a major strategy in the prevention of malaria in pregnancy. Although sulphadoxine-pyrimethamine (SP) is currently recommended for intermittent preventive treatment of malaria during pregnancy in Nigeria, previously used...

  • Antimalarial activities of Some Selected Traditional Herbs from South Eastern Nigeria Against Plasmodium Species. Ogbonna, David N.; Sokari, Tokuibiye G.; Agomuoh, Anthony A. // Research Journal of Parasitology;2008, Vol. 3 Issue 1, p25 

    A study of three plants traditionally used in the treatment of malaria in the Southeastern part of Nigeria was investigated to determine their efficacies as antimalarial compounds. The three herbs were collected through a traditional herbalist who uses them in his practice. Ethanolic extracts...

  • Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries. Dow, Geoffrey S.; Jun Liu; Gina Lin; Hetzell, Brian; Thieling, Sarah; McCarthy, William F.; Tang, Douglas; Smith, Bryan // Malaria Journal;11/26/2015, Vol. 14 Issue 1, p1 

    Background: Tafenoquine is a long half-life primaquine analog being developed for malaria prophylaxis. The US Army recently performed a unified analysis of efficacy in preparation for a regulatory submission, utilizing legacy data from three placebo-controlled studies conducted in the late 1990s...

  • Research, Therapy, and Bioethical Hegemony: The Controversy over Perinatal AZT Trials in Africa. Wendland, Claire L. // African Studies Review;Dec2008, Vol. 51 Issue 3, p1 

    Research on zidovudine (AZT) for pregnant women in Africa sparked worldwide debate in the late 1990s. The debate ultimately led to the rewriting of international ethics guidelines, in at least one case specifically to prohibit use of a placebo group (the most controversial aspect of the...

  • Control of malaria in pregnancy: an elusive target. Brieger, William R. // Africa Health;Jan2012, Vol. 34 Issue 2, p15 

    The article outlines several initiatives designed to protect pregnant women against the damage cause from malaria in Africa. It mentions that the Intermittent Preventive Treatment in pregnancy (IPTp) entails giving at least two doses of an effective antimalarial drug at least one month apart...

  • Intermittent Preventive Treatment for Malaria in Papua New Guinean Infants Exposed to Plasmodium falciparum and P. vivax: A Randomized Controlled Trial Senn, Nicolas; Rarau, Patricia; Stanisic, Danielle I.; Robinson, Leanne; Barnadas, Céline; Manong, Doris; Salib, Mary; Iga, Jonah; Tarongka, Nandao; Ley, Serej; Rosanas-Urgell, Anna; Aponte, John J.; Zimmerman, Peter A.; Beeson, James G.; Schofield, Louis; Siba, Peter; Rogerson, Stephen J.; Reeder, John C.; Mueller, Ivo // PLoS Clinical Trials;Mar2012, Vol. 7 Issue 3, p1 

    A three-arm randomized trial conducted among infants in Papua New Guinea estimates the preventive effect against malaria episodes of intermittent preventive treatment, in an area where children are exposed to both falciparum and vivax malaria.

  • Bacterial Pore-Forming Cytolysins Induce Neuronal Damage in a Rat Model of Neonatal Meningitis. Reiß, Anja; Braun, Johann S.; Jäger, Katja; Freyer, Dorette; Laube, Gregor; Bührer, Christoph; Felderhoff-Muser, Ursula; Stadelmann, Christine; Nizet, Victor; Weber, Joerg R. // Journal of Infectious Diseases;2/1/2011, Vol. 203 Issue 3, p393 

    Background. Group B Streptococcus (GBS) and Streptococcus pneumoniae (SP) are leading causes of bacterial meningitis in neonates and children. Each pathogen produces a pore-forming cytolytic toxin, β-hemolysin/cytolysin (β-h/c) by GBS and pneumolysin by SP. The aim of this study was to...

  • Pregnancy and Travel. Barry, Michele; Bia, Frank // JAMA: Journal of the American Medical Association;2/3/89, Vol. 261 Issue 5, p728 

    Focuses on special problems of travel during pregnancy. Optimal maintenance of fetal and maternal health; Clinical examination of questions regarding immunizations, antimalarials and therapy for traveler's diarrhea; Risks of high altitude or vigorous exercise for pregnant women.

  • Does oral metronidazole prevent preterm delivery in normal-risk pregnant women with asymptomatic bacterial vaginosis (BV)? Lazar, Paul A. // Journal of Family Practice;Jun2000, Vol. 49 Issue 6, p495 

    The article discusses research being done on the effectiveness of metronidazole to prevent pre-term delivery in pregnant women with asymptomatic bacterial vaginosis, with reference to a study by J. C. Carey, M. A. Klebanoff, J. C. Hauth, et al, which appeared in the 2000 issue of the "New...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics